Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer with Macrovascular Invasion (HELIO-RT)
Principal Investigator
Jennifer Wo, MD,
Status
Open to Accrual
Date Opened To Accrual
October 07 2025
Disease Site
Gastrointestinal [GI]
Other
Phase
III
Developmental Therapeutics
No
Primary Objective
To determine if liver SBRT in combination with IO-based systemic therapy improves survival compared to IO-based systemic therapy alone, in patients with hepatocellular cancer with macrovascular invasion.
Patient Population
Diagnosis of hepatocellular cancer (HCC). HCCmacrovascular invasion, defined as enhancing vascular thrombosis demonstratingarterial enhancement and venous or delayed venous washout on multiphasic MRIand/or CT.
Target Accrual
226
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.